Les myélofibroses

Genthon, Alexis; Killian, Martin; Mertz, Philippe; Cathébras, P.; Mestral, Santiago Gimenez de; Guyotat, D.; Chalayer, Emilie

doi:10.1016/j.revmed.2020.08.018

Cited by 5 publications

(2 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On February 28, 2022, the FDA granted accelerated approval to Pacritinib, a highly effective inhibitor of JAK2 and FMS-like tyrosine kinase 3 (FLT3), which was used to treat adult patients with low platelets who suffer from intermediate or high-risk primary or secondary myelofibrosis (MF) [ 127 , 128 ]. Pacritinib potently inhibits wild-type JAK2 (IC 50 = 23 nM), JAK2 V617F (IC 50 = 19 nM), FLT3 (IC 50 = 22 nM), and FLT3 D835Y (IC 50 = 6 nM) [ 129 ], which benefits the signaling of many growth factors and cytokines associated with immune and hematopoiesis function.…”

Section: Hematologic Drugsmentioning

confidence: 99%

Synthesis and clinical application of new drugs approved by FDA in 2022

Zhang,

Wang,

Sun

et al. 2023

Mol Biomed

View full text Add to dashboard Cite

The pharmaceutical industry had a glorious year in 2022, with a total of 37 new drugs including 20 new chemical entities (NCEs) and 17 new biological entities (NBEs) approved by the Food and Drug Administration (FDA). These drugs are mainly concentrated in oncology, central nervous system, antiinfection, hematology, cardiomyopathy, dermatology, digestive system, ophthalmology, MRI enhancer and other therapeutic fields. Of the 37 drugs, 25 (68%) were approved through an expedited review pathway, and 19 (51%) were approved to treat rare diseases. These newly listed drugs have unique structures and new mechanisms of action, which can serve as lead compounds for designing new drugs with similar biological targets and enhancing therapeutic efficacy. This review aims to outline the clinical applications and synthetic methods of 19 NCEs newly approved by the FDA in 2022, but excludes contrast agent (Xenon Xe-129). We believe that an in-depth understanding of the synthetic methods of drug molecules will provide innovative and practical inspiration for the development of new, more effective, and practical synthetic techniques. According to the therapeutic areas of these 2022 FDA-approved drugs, we have classified these 19 NCEs into seven categories and will introduce them in the order of their approval for marketing.

show abstract

Section: Hematologic Drugsmentioning

confidence: 99%

Synthesis and clinical application of new drugs approved by FDA in 2022

Zhang,

Wang,

Sun

et al. 2023

Mol Biomed

View full text Add to dashboard Cite

show abstract

“…Other common mutations include those of calreticulin (CALR) and of myeloproliferative leukemia virus oncogene (MPL) which make up 25% and 7% of PMF cases, respectively [4]. These mutations are believed to start clonal myeloproliferation, leading to clinical presentation including anemia, hepatosplenomegaly, and systemic symptoms like fatigue, night sweats, and low-grade fever [5].…”

Section: Introductionmentioning

confidence: 99%